Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Jiangsu gdk Biotechnology Co Days Payable?
Jiangsu gdk Biotechnology CoSHSE:688670 +0.63%61 Days Payable is 2,724.45 as of Jun. 2026, which is 264% above its 10-year median of 749.44. GuruFocus rates SHSE:688670 with a GF Score™ of 61/100 and a GF Value™ of ¥17.95 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 709 Biotechnology companies, Jiangsu gdk Biotechnology Co ranks better than 81.66% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688670 vs VRTX, REGN, MRNA: Days Payable Comparison
For the Biotechnology subindustry, Jiangsu gdk Biotechnology Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu gdk Biotechnology Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jiangsu gdk Biotechnology Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Jiangsu gdk Biotechnology Co's Days Payable falls into.
Jiangsu gdk Biotechnology Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu gdk Biotechnology Co (SHSE:688670) has a Days Payable of 2,724.45 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Jiangsu gdk Biotechnology Co and its competitors. This is 264% above median its historical median of 749.44. Over the past decade, Jiangsu gdk Biotechnology Co's Days Payable has ranged from 126.69 to 1,134.16. According to the industry distribution chart, Jiangsu gdk Biotechnology Co ranks #130 out of 709 companies in the Biotechnology industry, placing it in the top 18.3%.
Is Jiangsu gdk Biotechnology Co's Days Payable too high?
Jiangsu gdk Biotechnology Co's current Days Payable of 2,724.45 is 264% above median its 10-year median of 749.44. Over the past 10 years, this metric has ranged from a low of 126.69 to a high of 1,134.16. The Biotechnology industry median Days Payable is 111.24. Jiangsu gdk Biotechnology Co's value of 2,724.45 is 2349.2% above this industry median. Based on the distribution chart, Jiangsu gdk Biotechnology Co ranks #130 out of 709 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Jiangsu gdk Biotechnology Co has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu gdk Biotechnology Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jiangsu gdk Biotechnology Co ranks #130 out of 709 companies for Days Payable. This places Jiangsu gdk Biotechnology Co in the top 18% of its industry — outperforming the majority of peers. The industry median Days Payable is 111.24. Jiangsu gdk Biotechnology Co's value of 2,724.45 is 2349.2% above this benchmark. Historically, Jiangsu gdk Biotechnology Co's own Days Payable has ranged from 126.69 to 1,134.16 over the past decade. While the company's 10-year median is 749.44 vs. the industry median of 111.24, Jiangsu gdk Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.24, based on 709 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu gdk Biotechnology Co's current Days Payable of 2,724.45 is 2349.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Jiangsu gdk Biotechnology Co and its competitors. For the Biotechnology industry, the median Days Payable is 111.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu gdk Biotechnology Co's current Days Payable is 2,724.45, which is 264% above median its own 10-year median of 749.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu gdk Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu gdk Biotechnology Co (SHSE:688670) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥17.95, compared to a current price of ¥16.05 — trading 10.6% below its estimated fair value. The current Days Payable is 2,724.45, which is 264% above median its 10-year median of 749.44 and 2349.2% above the Biotechnology industry median of 111.24. Jiangsu gdk Biotechnology Co's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Jiangsu gdk Biotechnology Co (SHSE:688670), the current Days Payable is 2,724.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu gdk Biotechnology Co (SHSE:688670) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu gdk Biotechnology Co stock appears to be undervalued.
The current stock price of ¥16.05 is trading 10.6% below its estimated GF Value™ of ¥17.95.
GuruFocus considers Jiangsu gdk Biotechnology Co to be Modestly Undervalued.
Key valuation signals for SHSE:688670:
Days Payable: 2,724.45 (264% above median its 10-year median of 749.44)
GF Value™: ¥17.95 vs. price of ¥16.05 (10.6% below fair value)
Industry Position: 2349.2% above the Biotechnology median (#130 of 709)
No single metric tells the full story. See the SHSE:688670 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu gdk Biotechnology Co Ltd is a biological high-tech enterprise integrating scientific research, production, operation and service of human vaccines. The company's product pipeline covers prevention of five important infectious diseases such as influenza, rabies, chickenpox, shingles and pneumonia.
61GF Score
Get the complete analysis for SHSE:688670
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688670 has been successfully added to your 
